Showing 4401-4410 of 9330 results for "".
- Changes Afoot at Valeant Pharmaceuticalshttps://practicaldermatology.com/news/changes-afoot-at-valeant-pharmaceuticals/2458527/Amid reports that its Obagi Medical Products and Solta Medical units are on the block, Valeant Pharmaceuticals is assuring investors that the company is focused on the future and has plans to fix its dermatology unit. Valeant CEO Joseph Papa cited the company’s strengths during the company’s annu…
- Galderma's Cetaphil® Launches Limited-edition Product Display Honoring Camp Wonderhttps://practicaldermatology.com/news/galdermas-cetaphil-launches-limited-edition-product-display-honoring-camp-wonder/2458529/Galderma Laboratories is unveiling a limited-edition product display in partnership with the Children's Skin Disease Foundation (CSDF) and Camp Wonder, an initiative of the CSDF. As part of a five-year partnership with the Camp Wonder program, Cetaphil Moisturizing Cream is being showcased exclus…
- UCB: Investigational Bimekizumab Helps Psoriatic Arthritis in Phase 1Bhttps://practicaldermatology.com/news/ucb-investigational-bimekizumab-helps-psoriatic-arthritis-in-phase-1b/2458534/Bimekizumab, in development by UCB, has shown promise for the treatment of psoriatic arthritis (PsA) in Phase 1B studies. For the study, a total of 52 PsA patients inadequately controlled with at least one disease-modifying anti-rheumatic drug (DMARD) and/or one biologic were randomized to receive …
- Kate Bosworth Partners with Allergan for ACZONE® Gel, 7.5% Launchhttps://practicaldermatology.com/news/kate-bosworth-partners-with-allergan-for-aczone-gel-75-launch/2458540/Actress, producer and model Kate Bosworth is the new face of Allergan plc’s ACZONE® (dapsone) Gel, 7.5%. ACZONE® Gel, 7.5% is a once-a-day prescription topical treatment for acne in patients 12 years of age and older. It was approved by the U.S. Food and Drug Administration in February 2016 Boswo…
- Allergan's TEFLARO® OK'd for Pediatric Patientshttps://practicaldermatology.com/news/allergans-teflaro-oked-for-pediatric-patients/2458547/Allergan’s TEFLARO® (ceftaroline fosamil) is now indicated for pediatric patients, making it the first branded IV antibiotic approved for this population in more than a decade. The U.S. Food and Drug Administration (FDA) approved the company's supplemental New Drug Application (sNDA) allowing the …
- Galderma Introduces New Mirvaso Pump Dispenser to Treat Persistent Facial Redness of Rosaceahttps://practicaldermatology.com/news/galderma-introduces-new-mirvaso-pump-dispenser-to-treat-persistent-facial-redness-of-rosacea/2458549/Galderma Laboratories, L.P. launched a new pump dispenser design for Mirvaso (brimonidine) Topical Gel, 0.33% for the treatment of the persistent facial redness associated with rosacea. The Mirvaso Gel Pump is now available by prescription to patients in pharmacies nationwide. The improved deliver…
- Robert Grant No Longer CEO of Alphaeonhttps://practicaldermatology.com/news/robert-grant-no-longer-ceo-of-alphaeon/2458550/Robert Grant is no longer CEO of Alphaeon, our sister site, Eyewiretoday.com has learned. After 3 years at the helm of the lifestyle healthcare company, Mr. Grant is relinquishing the leadership role of the company he founded.
- FDA Accepts Allergan's NDA Filing for Oxymetazoline HCI Cream 1.0% for Facial Erythemahttps://practicaldermatology.com/news/fda-accepts-allergans-nda-filing-for-oxymetazoline-hci-cream-10/2458553/The FDA accepted Allergan plc's New Drug Application (NDA) filing for oxymetazoline HCl cream 1.0%, an investigational topical prescription product for the treatment of persistent facial erythema (redness) associated with rosacea in adults. Allergan expects the Prescription Drug User Fee Act (PDUFA…
- Congrats: Dr. Barbara Gilchrest Receives the 24th David Martin Carter Mentor Awardhttps://practicaldermatology.com/news/congrats-dr-barbara-gilchrest-receives-the-24th-david-martin-carter-mentor-award/2458556/Barbara A. Gilchrest, MD of Harvard Medical School and Massachusetts General Hospital in Boston received the David Martin Carter Mentor Award at the Annual Meeting of the Society for Investigative Dermatology in Scottsdale, Ariz. Dr. Gilchrest plus the recipients of The Research Achievement Awards…
- AXIM Biotech Begins Clinical Trials With Cannabigerol for Psoriasis and Eczemahttps://practicaldermatology.com/news/axim-biotech-begins-clinical-trials-with-cannabigerol-for-psoriasis-and-eczema/2458562/AXIM Biotechnologies, Inc. launched human dermatological clinical trials based on its proprietary, patent-pending topical ointment formulation AX-1602 that includes the "stem cell cannabinoid" cannabigerol (CBG) and other cannabinoids. The two indications for AXIM's AX-1602 in human trials are Psor…